Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

The top 10 med-tech stock gainers and losers for the week.

The top 10 biopharma stock gainers and losers for the week.

Med-tech has seen significant deal value growth during the first four months of 2023, despite a decline in the number of deals. In contrast, the value of mergers and acquisitions has experienced a notable downturn.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.